Xeris Biopharma Holdings Files 8-K on Shareholder Votes
Ticker: XERS · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1867096
| Field | Detail |
|---|---|
| Company | Xeris Biopharma Holdings, Inc. (XERS) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
Xeris Biopharma filed an 8-K on June 4, 2025, detailing shareholder votes. Important governance update.
AI Summary
Xeris Biopharma Holdings, Inc. filed an 8-K on June 4, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate actions and decisions made during this period, as required by SEC regulations.
Why It Matters
This filing provides transparency into key corporate governance decisions and shareholder approvals, which can impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of shareholder voting matters and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Xeris Biopharma Holdings, Inc. (company) — Registrant
- June 4, 2025 (date) — Date of Report
- 1375 West Fulton Street, Suite 1300 Chicago, Illinois 60607 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Xeris Biopharma Holdings, Inc.?
The primary purpose of this 8-K filing is to report on matters submitted to a vote of security holders, as indicated by the 'Submission of Matters to a Vote of Security Holders' item information.
On what date was this 8-K report filed?
This 8-K report was filed on June 4, 2025.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Xeris Biopharma Holdings, Inc.
Where are Xeris Biopharma Holdings, Inc.'s principal executive offices located?
Xeris Biopharma Holdings, Inc.'s principal executive offices are located at 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607.
What is the Commission File Number for Xeris Biopharma Holdings, Inc.?
The Commission File Number for Xeris Biopharma Holdings, Inc. is 001-40880.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Xeris Biopharma Holdings, Inc. (XERS).